Human antibodies to crimean congo hemorrhagic fever virus
AssigneeVanderbilt University
InventorJames E. CROWE, Jr.
Life of this patent
Estimating the term…
Abstract
The present disclosure is directed to antibodies binding to and neutralizing Crimean Congo Hemorrhagic Fever Virus and methods for use thereof.
Claims27
A method of detecting a Crimean Congo Hemorrhagic Fever Virus infection in a subject comprising:
- (a) contacting a sample from said subject with an antibody or antibody fragment having clone-paired heavy and light chain CDR sequences from Tables 3 and 4, respectively;
- and
- (b) detecting Crimean Congo Hemorrhagic Fever Virus in said sample by binding of said antibody or antibody fragment to a Crimean Congo Hemorrhagic Fever Virus antigen in said sample.
-12. (canceled)
A method of treating a subject infected with Crimean Congo Hemorrhagic Fever Virus or reducing the likelihood of infection of a subject at risk of contracting Crimean Congo Hemorrhagic Fever Virus, comprising delivering to said subject an antibody or antibody fragment having clone-paired heavy and light chain CDR sequences from Tables 3 and 4, respectively.
A monoclonal antibody, wherein the antibody or antibody fragment is characterized by clone-paired heavy and light chain CDR sequences from Tables 3 and 4, respectively.
-35. (canceled)
A hybridoma or engineered cell encoding an antibody or antibody fragment wherein the antibody or antibody fragment is characterized by clone-paired heavy and light chain CDR sequences from Tables 3 and 4, respectively.
-46. (canceled)
A vaccine formulation comprising one or more antibodies or antibody fragments characterized by clone-paired heavy and light chain CDR sequences from Tables 3 and 4, respectively, or one or more expression vectors encoding a first antibody or antibody fragment comprising one or more antibodies or antibody fragments characterized by clone-paired heavy and light chain CDR sequences from Tables 3 and 4, respectively.
-71. (canceled)
(canceled)
(canceled)
A method of determining the antigenic integrity, correct conformation and/or correct sequence of a Crimean Congo Hemorrhagic Fever Virus antigen comprising:
- (a) contacting a sample comprising said antigen with a first antibody or antibody fragment having clone-paired heavy and light chain CDR sequences from Tables 3 and 4, respectively;
- and
- (b) determining antigenic integrity, correct conformation and/or correct sequence of said antigen by detectable binding of said first antibody or antibody fragment to said antigen.
77-96. (canceled)
Dependencies are inferred from the claim text.